ACKR3
ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Atypical chemokine receptor that controls chemokine levels and localisation via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalising receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalisation and activation of MAPK signalling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Location: Cell membrane; Early endosome; Recycling endosome (UniProt). Locus 2q37.3 (HGNC).
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"ACKR3" OR ABSTRACT:"ACKR3" OR TITLE:"atypical chemokine receptor 3" OR ABSTRACT:"atypical chemokine receptor 3" OR TITLE:"Atypical chemokine receptor 3" OR ABSTRACT:"Atypical chemokine receptor 3" OR TITLE:"RDC1" OR ABSTRACT:"RDC1" OR TITLE:"GPR159" OR ABSTRACT:"GPR159" OR TITLE:"CMKOR1" OR ABSTRACT:"CMKOR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACKR3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ackr3.json. Licence CC BY-NC 4.0.